... to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements. Juvenile Paget disease Denosumab Bisphosphonates Growth hormone Linear growth Height velocity Receptor activator of nuclear factor-κB ligand Juvenile Paget...

... ranges has limited the application of CNP measurements in clinical practice. Plasma concentrations of the processed product of proCNP, NTproCNP – and to a lesser extent CNP itself – correlate with concurrent height velocity throughout all phases of normal skeletal growth, as well as during interventions...

... South Korea between December 2012 and March 2015. The primary endpoint was difference in height velocity from baseline to 6 months in the treatment and control arms. Results: 97 children were screened; 90 were randomly assigned: 60 children to 0.067 mg/kg/day r-hGH for 12 months (treatment) and 30...

... (control, n = 16), LB03002 0.5 mg/kg/week ( n = 14), or LB03002 0.7 mg/kg/week ( n = 16). The primary endpoint was height velocity (HV) change at week 26. Results: At week 26, the least square (LS) means for HV change (cm/year) with control, LB03002 0.5 mg/kg/week, and LB03002 0.7 mg/kg/week were 5.08...

...), other diseases (n = 46) or syndromes (n = 48) were evaluated in this retrospective multicenter study. Median age at GH start was 6.3 years and Ht SDS –3.2. Results: Median [25–75 percentile] first-year gain in Ht SDS was 0.65 (0.40–0.90) and height velocity (HtV) 8.67 (7.51–9.90) cm/year. Almost 50...

... of auxological data up to final height in a cohort of patients with perinatal HIV infection. Patients and Methods: In 95 Caucasian patients (57 females and 38 males, median age 17.5 years) the following data were evaluated as standard deviation (SD) score: prepubertal height (PrH), height velocity (HV), final...

... is assessed with height, short-term changes in height velocity (HV), and attainment of final adult height, which may not be concordant. In both children and adults, the biochemical indices utilized to predict and/or monitor response to GH therapy have included: (1) nonspecific indices: glucose, insulin, urea...

... with the anabolic steroid oxandrolone (Oxa) on height velocity and on Turner-specific bone age (BA’TS) and, second, to estimate the gain in final height taking the age at the onset of treatment into account. The mean advancement of BA’TS in 2 years of treatment was 2.5 years/2 years in group 1 (low dose GH: 16 IU/m...

... of height velocity and bone maturation normalized, and the predicted adult height increased significantly by a mean of 1.5 cm/treatment year. After cessation of depot triptorelin treatment, the mean height prediction decreased slightly and the approximate adult height remained comparable with the predicted...

... prophylaxis and systemic chemotherapy including glucocorticoid. The mean age at onset of the pubertal growth spurt in these 6 girls was significantly lower than for girls with a solid tumor [6.90 ± 0.10 and 9.00 ± 0.77 (mean ± SD) years, respectively (p < 0.001)]. By simply evaluating the height velocity...

...H.L. Lenko; A. Hakulinen; M.-L. Käär; J. Mäenpää; A.-L. Mäkelä; I. Sipilä The aims of this national multicentre study in Finland were to evaluate whether the height velocity of patients with Turner syndrome would increase with the conventional human growth hormone (GH) therapy regimen normally...

..., and group B 12-19 years) and human growth hormone (GH) dose regimen (Al and Bl, three injections/week; A2 and B2, six injections/week). All groups responded to GH, 24 IU/m 2 /week, with an increase in height velocity, though in the older girls, the response was comparatively poor. Therefore, the dose...

... this period. The low incidence of adverse medical problems during GH treatment complemented its efficacy. Height velocity in the first year was 7.7 ± 1.8 cm/year (mean ± SD) and was correlated with maternal height SDS, though not with paternal height SDS. Some 36% of first-year height velocity SDS could...

... treatment groups showed a statistically significant increase in growth during treatment. However, the higher dose increased height velocity to a significantly greater extent during the first and second year of treatment. The projected adult height was exceeded by 52 of 71 patients over the age of 14 years...

... the following inclusion criteria: isolated GHD, >2 years growth hormone therapy prior to puberty onset, regular weight-adjusted GH dosage, known final height (age >21 years or height velocity <0.5 cm/year), no induction of puberty. PB1 was used to define age and height at onset of the pubertal growth...

...W.J.M. Gerver; R. de Bruin Normal values are given for height velocity in a Dutch population. A construction of velocity curves is given and a comparison is made with other studies. 28 10 2002 6 06 2003 15 10 2003 © 2003 S. Karger AG, Basel 2003 Copyright / Drug Dosage...

...M.V.L. Du Caju; L. Op De Beeck; S.U. Sys; M.M. Hagendorens; R.P.A. Rooman Objective: To describe the prepubertal growth pattern in boys with delayed puberty. Methods: Growth curves for height and height velocity covering the age range 4–14 years were constructed on the basis of retrospectively...

.... It reports on the diagnostic validity of height velocity over 1, 2 or 3 years for isolated idiopathic growth hormone deficiency and for Turner syndrome in prepubertal children with a height that is still above –2.5 standard deviation scores (SDS). 1-year height velocity was found to have no diagnostic value...